98%
921
2 minutes
20
Chemotherapy-induced peripheral neuropathy (CIPN) is often an overlooked side effect, affecting cancer patients' quality of life. Improving this requires an in-depth understanding of how patients perceived their CIPN experience, which this study had explored. This study also sought to identify potential barriers to current CIPN management among Malaysian cancer patients. Semi-structured one-to-one interviews were conducted among cancer patients who had a confirmed diagnosis of CIPN from one hospital and a local cancer organization. Interviews were conducted until theme saturation was achieved (N = 22). Interviews were audio-recorded, transcribed verbatim, and analysed using thematic analysis. Three main themes emerged: manageable CIPN experiences impacting activities of daily living despite limited awareness, current conventional treatments of CIPN were partially effective with side effects, and explorative of alternative treatment options for CIPN. The study results indicated that patients experienced CIPN, which was considerably mild and impacted their life activities to a small extent. The limited information provided about CIPN contributed to a sense of uncertainty among patients. They emphasized the importance of more accessible information and education about CIPN and its management. Although the conventional management of CIPN was able to partly control symptoms, patients experienced side effects from the prescribed medications. Interestingly, patients expressed openness to explore new treatments to help them cope better with CIPN. These findings highlighted the need for a comprehensive, patient-centred approach to CIPN management. Insights from patient experiences could guide the development of educational interventions, such as patient's assessment form on CIPN experiences and awareness activities to enhance CIPN care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13187-025-02624-z | DOI Listing |
Korean J Clin Oncol
August 2025
Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with oxaliplatin-based chemotherapy in gastric cancer patients. Recent studies suggest that high-dose intravenous selenium may exert neuroprotective effects in patients receiving platinum-based chemotherapy.
Methods: This pilot study analyzed patients with stage III gastric adenocarcinoma who underwent gastrectomy between January and December 2024.
Mol Pain
September 2025
The Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Background: Chronic pain and cancer interact bidirectionally, with pain enhancing sensory peptides and potentially promoting tumor growth. Despite this, most chemotherapy-induced neuropathic pain (CIPN) studies overlook the contribution of cancer itself to neuropathy, focusing instead on chemotherapy-induced mechanisms. Animal models of chemotherapy-induced neuropathic pain (CINP) have been developed by injecting chemotherapeutic drugs such as paclitaxel into normal animals without cancer.
View Article and Find Full Text PDFCureus
August 2025
Department of Gastrointestinal Surgery, Panasonic Health Insurance Organization, Matsushita Memorial Hospital, Osaka, JPN.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of several anticancer agents, leading to impaired physical function and quality of life. Although exercise therapy and physical modalities such as transcutaneous electrical nerve stimulation have been reported to alleviate CIPN symptoms, the efficacy of alternating magnetic field therapy remains unclear. We here report a rectal cancer survivor who experienced difficulty returning to work due to persistent neuropathic symptoms of CIPN.
View Article and Find Full Text PDFClin Breast Cancer
August 2025
Tangshan Maternal and Child Health Care Hospital, Tangshan, China. Electronic address:
Objective: To explore the trajectory patterns and influencing factors of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients using latent class growth analysis (LCGA).
Methods: This study was conducted from September 2022 to September 2023 at a tertiary hospital in Tangshan, China. A total of 350 hospitalized breast cancer patients undergoing chemotherapy were recruited.
Pain
September 2025
Department of Pharmacology and Physiology, The Institute for Translational Neuroscience, Saint Louis University School of Medicine, St. Louis, MO, United States.
Chemotherapy-induced peripheral neuropathy accompanied by neuropathic pain (CIPN) is a major neurotoxicity of cisplatin, a platinum-based drug widely used for lung, ovarian, and testicular cancer treatment. Chemotherapy-induced peripheral neuropathy accompanied by neuropathic pain causes drug discontinuation and severely affects life quality with no FDA-approved interventions. We previously reported that platinum-based drugs increase levels of sphingosine 1-phosphate (S1P) in the spinal cord and drive CIPN through activating the S1P receptor subtype 1 (S1PR1).
View Article and Find Full Text PDF